Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029

1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 35 1.3.2 INCLUSIONS AND EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 37 1.4 CURRENCY CONSIDERED 37 1.5 STAKEHOLDERS 37 1.6 SUMMARY OF CHANGES 38 2 RESEARCH METHODOLOGY 39 2.1 RESEARCH DATA 39 2.1.1 SECONDARY DATA 40 2.1.2 PRIMARY DATA 40 2.2 MARKET SIZE ESTIMATION METHODOLOGY 41 2.2.1 PRECISION DIAGNOSTICS MARKET 41 2.2.2 PRECISION MEDICINE MARKET 44 2.2.3 INSIGHTS FROM PRIMARY SOURCES 46 2.3 TOP-DOWN APPROACH 47 2.3.1 PRECISION DIAGNOSTICS MARKET 47 2.3.2 PRECISION MEDICINE MARKET 48 2.4 GROWTH FORECAST MODEL 49 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 51 2.6 RESEARCH ASSUMPTIONS 52 2.7 RESEARCH LIMITATIONS 52 2.8 RISK ANALYSIS 52 3 EXECUTIVE SUMMARY 53 4 PREMIUM INSIGHTS 58 4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW 58 4.2 PRECISION MEDICINE MARKET OVERVIEW 59 4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023 60 4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 60 4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023 61 4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023 61 4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 62 4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62 4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63 5 MARKET OVERVIEW 64 5.1 INTRODUCTION 64 5.2 MARKET DYNAMICS 64 5.2.1 DRIVERS 65 5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies 65 5.2.1.2 Rise in direct-to-consumer testing 66 5.2.1.3 Growing integration of artificial intelligence and machine learning 66 5.2.2 RESTRAINTS 67 5.2.2.1 High cost of precision healthcare 67 5.2.3 OPPORTUNITIES 67 5.2.3.1 Expanding applications of precision healthcare 67 5.2.3.2 Growing adoption of wearable devices 68 5.2.4 CHALLENGES 68 5.2.4.1 Complex regulatory approval landscape 68 5.2.4.2 Big data management and integration issues 69 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69 5.4 PRICING ANALYSIS 70 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 70 5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER 72 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 73 5.5 VALUE CHAIN ANALYSIS 74 5.5.1 PRECISION DIAGNOSTICS MARKET 74 5.5.2 PRECISION MEDICINE MARKET 76 5.6 SUPPLY CHAIN ANALYSIS 77 5.6.1 PRECISION DIAGNOSTICS MARKET 77 5.6.2 PRECISION MEDICINE MARKET 78 5.7 ECOSYSTEM ANALYSIS 79 5.8 PIPELINE ANALYSIS 81 5.9 DIAGNOSTIC PRODUCT ANALYSIS 83 5.10 INVESTMENT/FUNDING ACTIVITY 96 5.11 TECHNOLOGY ANALYSIS 97 5.11.1 KEY TECHNOLOGIES 97 5.11.1.1 Next-generation sequencing 97 5.11.1.2 Immunohistochemistry 97 5.11.1.3 Liquid biopsy 97   5.11.2 COMPLEMENTARY TECHNOLOGIES 98 5.11.2.1 Single-cell analysis 98 5.11.2.2 AI and ML integration 98 5.11.3 ADJACENT TECHNOLOGIES 98 5.11.3.1 Theranostics 98 5.11.3.2 Imaging technologies 99 5.12 PATENT ANALYSIS 99 5.13 TRADE ANALYSIS 102 5.13.1 IMPORT DATA 102 5.13.2 EXPORT DATA 104 5.14 KEY CONFERENCES AND EVENTS, 2025–2026 106 5.15 REGULATORY LANDSCAPE 107 5.15.1 REGULATORY ANALYSIS 107 5.15.1.1 North America 107 5.15.1.2 Europe 108 5.15.1.3 Asia Pacific 108 5.15.1.4 Rest of the World 108 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 5.16 PORTER’S FIVE FORCES ANALYSIS 112 5.16.1 PRECISION DIAGNOSTICS MARKET 112 5.16.1.1 Threat of new entrants 113 5.16.1.2 Threat of substitutes 113 5.16.1.3 Bargaining power of buyers 114 5.16.1.4 Bargaining power of suppliers 114 5.16.1.5 Intensity of competitive rivalry 114 5.16.2 PRECISION MEDICINE MARKET 114 5.16.2.1 Threat of new entrants 115 5.16.2.2 Threat of substitutes 115 5.16.2.3 Bargaining power of buyers 115 5.16.2.4 Bargaining power of suppliers 116 5.16.2.5 Intensity of competitive rivalry 116 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA 116 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 116 5.17.2 BUYING CRITERIA 119 5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET 121 5.18.1 INTRODUCTION 121 5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES 121 5.18.3 AI USE CASES 122 5.18.4 KEY COMPANIES IMPLEMENTING AI 123 5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM 123 6 PRECISION DIAGNOSTICS MARKET, BY TYPE 124 6.1 INTRODUCTION 125 6.2 GENETIC TESTING 125 6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH 125 6.3 DTC TESTING 127 6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH 127 6.4 OTHER TYPES 130 7 PRECISION DIAGNOSTICS MARKET, BY INDICATION 132 7.1 INTRODUCTION 133 7.2 ONCOLOGY 133 7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH 133 7.3 NEUROLOGY 136 7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET 136 7.4 IMMUNOLOGY 138 7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET 138 7.5 OTHER DIAGNOSTIC INDICATIONS 140 8 PRECISION DIAGNOSTICS MARKET, BY END USER 143 8.1 INTRODUCTION 144 8.2 CLINICAL LABORATORIES 144 8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH 144 8.3 HOSPITALS 146 8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET 146 8.4 HOME CARE SETTINGS 148 8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH 148 9 PRECISION MEDICINE MARKET, BY PRODUCT 151 9.1 INTRODUCTION 152 9.2 MONOCLONAL ANTIBODIES 152 9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH 152 9.3 INHIBITOR DRUGS 154 9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH 154 9.4 CELL & GENE THERAPIES 157 9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET 157   9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS 159 9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH 159 9.6 OTHER PRODUCTS 161 10 PRECISION MEDICINE MARKET, BY INDICATION 164 10.1 INTRODUCTION 165 10.2 ONCOLOGY 165 10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET 165 10.3 RARE DISEASES 167 10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH 167 10.4 INFECTIOUS DISEASES 170 10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET 170 10.5 HEMATOLOGICAL DISORDERS 172 10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH 172 10.6 OTHER MEDICINE INDICATIONS 174 11 PRECISION MEDICINE MARKET, BY END USER 177 11.1 INTRODUCTION 178 11.2 HOSPITALS & CLINICS 178 11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET 178 11.3 HOME CARE SETTINGS 180 11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH 180 12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION 183 12.1 INTRODUCTION 184 12.2 NORTH AMERICA 184 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 188 12.2.2 US 189 12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth 189 12.2.3 CANADA 191 12.2.3.1 Growing cancer burden to support growth 191 12.3 EUROPE 194 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 198 12.3.2 GERMANY 199 12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market 199 12.3.3 UK 201 12.3.3.1 Favorable government support to expedite growth 201 12.3.4 FRANCE 204 12.3.4.1 Growing preference for personalized medicine to fuel market 204 12.3.5 ITALY 206 12.3.5.1 Rise in genomics research and diagnostic testing to foster growth. 206 12.3.6 SPAIN 208 12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth 208 12.3.7 REST OF EUROPE 211 12.4 ASIA PACIFIC 213 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216 12.4.2 CHINA 217 12.4.2.1 Growing regulatory approvals for precision medicines to boost market 217 12.4.3 JAPAN 219 12.4.3.1 Increasing availability of health insurance to encourage growth 219 12.4.4 INDIA 222 12.4.4.1 Rising burden of chronic diseases to promote growth 222 12.4.5 AUSTRALIA 224 12.4.5.1 Booming research & development investments to spur growth 224 12.4.6 REST OF ASIA PACIFIC 226 12.5 LATIN AMERICA 228 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 231 12.5.2 BRAZIL 232 12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market 232 12.5.3 MEXICO 235 12.5.3.1 Booming biopharmaceutical sector to contribute to growth 235 12.5.4 REST OF LATIN AMERICA 237 12.6 MIDDLE EAST & AFRICA 239 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 242 13 COMPETITIVE LANDSCAPE 244 13.1 OVERVIEW 244 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 244 13.2.1 PRECISION DIAGNOSTICS MARKET 244 13.2.2 PRECISION MEDICINE MARKET 247 13.3 REVENUE ANALYSIS, 2021–2023 252 13.3.1 PRECISION DIAGNOSTICS MARKET 252 13.3.2 PRECISION MEDICINE MARKET 253 13.4 MARKET SHARE ANALYSIS, 2023 254 13.4.1 PRECISION DIAGNOSTICS MARKET 254 13.4.2 PRECISION MEDICINE MARKET 257   13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 260 13.5.1 PRECISION DIAGNOSTICS MARKET 260 13.5.1.1 Stars 260 13.5.1.2 Emerging leaders 260 13.5.1.3 Pervasive players 260 13.5.1.4 Participants 261 13.5.1.5 Company footprint: Key players, 2023 262 13.5.1.5.1 Company footprint 262 13.5.1.5.2 Region footprint 263 13.5.1.5.3 Type footprint 264 13.5.1.5.4 Indication footprint 265 13.5.2 PRECISION MEDICINE MARKET 266 13.5.2.1 Stars 267 13.5.2.2 Emerging leaders 267 13.5.2.3 Pervasive players 267 13.5.2.4 Participants 267 13.5.2.5 Company footprint: Key players, 2023 269 13.5.2.5.1 Company footprint 269 13.5.2.5.2 Region footprint 270 13.5.2.5.3 Product footprint 271 13.5.2.5.4 Indication footprint 272 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 274 13.6.1 PRECISION DIAGNOSTICS MARKET 274 13.6.1.1 Progressive companies 274 13.6.1.2 Responsive companies 274 13.6.1.3 Dynamic companies 274 13.6.1.4 Starting blocks 274 13.6.1.5 Competitive benchmarking 276 13.6.1.5.1 Detailed list of key startups/SMES 276 13.6.1.5.2 Competitive benchmarking of startups/SMEs 277 13.6.2 PRECISION MEDICINE MARKET 278 13.6.2.1 Progressive companies 278 13.6.2.2 Responsive companies 278 13.6.2.3 Dynamic companies 278 13.6.2.4 Starting blocks 278 13.6.2.5 Competitive benchmarking 280 13.6.2.5.1 Detailed list of key startups/SMES 280 13.6.2.5.2 Competitive benchmarking of startups/SMEs 281 13.7 COMPANY VALUATION AND FINANCIAL METRICS 282 13.7.1 PRECISION DIAGNOSTICS MARKET 282 13.7.2 PRECISION MEDICINE MARKET 283   13.8 BRAND/PRODUCT COMPARISON 284 13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO 285 13.9.1 PRODUCT LAUNCHES AND APPROVALS 286 13.9.2 DEALS 287 13.9.3 EXPANSIONS 288 13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO 288 13.10.1 PRODUCT LAUNCHES AND APPROVALS 289 13.10.2 DEALS 290 13.10.3 EXPANSIONS 291 14 COMPANY PROFILES 292 14.1 KEY PLAYERS 292 14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS) 292 14.1.1.1 Business overview 292 14.1.1.2 Products offered 293 14.1.1.3 Recent developments 297 14.1.1.3.1 Product launches and approvals 297 14.1.1.3.2 Deals 298 14.1.1.4 MnM view 299 14.1.1.4.1 Key strengths 299 14.1.1.4.2 Strategic choices 299 14.1.1.4.3 Weaknesses and competitive threats 299 14.1.2 ABBOTT 300 14.1.2.1 Business overview 300 14.1.2.2 Products offered 301 14.1.2.3 Recent developments 302 14.1.2.3.1 Deals 302 14.1.2.4 MnM view 303 14.1.2.4.1 Key strengths 303 14.1.2.4.2 Strategic choices 303 14.1.2.4.3 Weaknesses and competitive threats 303 14.1.3 AGILENT TECHNOLOGIES, INC. 304 14.1.3.1 Business overview 304 14.1.3.2 Products offered 305 14.1.3.3 Recent developments 307 14.1.3.3.1 Product launches and approvals 307 14.1.3.3.2 Deals 308 14.1.3.3.3 Expansions 308 14.1.3.4 MnM view 308 14.1.3.4.1 Key strengths 308 14.1.3.4.2 Strategic choices 309 14.1.3.4.3 Weaknesses and competitive threats 309 14.1.4 GUARDANT HEALTH 310 14.1.4.1 Business overview 310 14.1.4.2 Products offered 311 14.1.4.3 Recent developments 312 14.1.4.3.1 Product launches and approvals 312 14.1.4.3.2 Deals 314 14.1.4.4 MnM view 315 14.1.4.4.1 Key strengths 315 14.1.4.4.2 Strategic choices 315 14.1.4.4.3 Weaknesses and competitive threats 315 14.1.5 EXACT SCIENCES CORPORATION 316 14.1.5.1 Business overview 316 14.1.5.2 Products offered 317 14.1.5.3 Recent developments 318 14.1.5.3.1 Product launches and approvals 318 14.1.5.3.2 Deals 319 14.1.5.4 MnM view 319 14.1.5.4.1 Key strengths 319 14.1.5.4.2 Strategic choices 319 14.1.5.4.3 Weaknesses and competitive threats 319 14.1.6 QIAGEN 320 14.1.6.1 Business overview 320 14.1.6.2 Products offered 321 14.1.6.3 Recent developments 324 14.1.6.3.1 Product launches and approvals 324 14.1.6.3.2 Deals 325 14.1.7 MYRIAD GENETICS, INC. 326 14.1.7.1 Business overview 326 14.1.7.2 Products offered 327 14.1.7.3 Recent developments 329 14.1.7.3.1 Product launches and approvals 329 14.1.7.3.2 Deals 329 14.1.7.3.3 Other developments 330 14.1.8 NATERA, INC. 331 14.1.8.1 Business overview 331 14.1.8.2 Products offered 332 14.1.8.3 Recent developments 334 14.1.8.3.1 Product launches and approvals 334 14.1.8.3.2 Deals 334 14.1.9 ILLUMINA, INC. 335 14.1.9.1 Business overview 335 14.1.9.2 Products offered 336 14.1.9.3 Recent developments 337 14.1.9.3.1 Product launches and approvals 337 14.1.9.3.2 Deals 337 14.1.10 THERMO FISHER SCIENTIFIC INC. 339 14.1.10.1 Business overview 339 14.1.10.2 Products offered 340 14.1.10.3 Recent developments 341 14.1.10.3.1 Product launches and approvals 341 14.1.10.3.2 Deals 342 14.1.11 DANAHER 344 14.1.11.1 Business overview 344 14.1.11.2 Products offered 345 14.1.11.3 Recent developments 348 14.1.11.3.1 Product launches and approvals 348 14.1.11.3.2 Deals 349 14.1.12 23ANDME, INC. 350 14.1.12.1 Business overview 350 14.1.12.2 Products offered 351 14.1.12.3 Recent developments 353 14.1.12.3.1 Deals 353 14.1.13 MERCK & CO., INC. 354 14.1.13.1 Business overview 354 14.1.13.2 Products offered 355 14.1.13.3 Recent developments 356 14.1.13.3.1 Product launches and approvals 356 14.1.13.3.2 Deals 360 14.1.14 GILEAD SCIENCES, INC. 361 14.1.14.1 Business overview 361 14.1.14.2 Products offered 362 14.1.14.3 Recent developments 364 14.1.14.3.1 Product launches and approvals 364 14.1.14.3.2 Deals 365 14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE) 367 14.1.15.1 Business overview 367 14.1.15.2 Products offered 368 14.1.15.3 Recent developments 371 14.1.15.3.1 Product launches and approvals 371 14.1.16 BRISTOL-MYERS SQUIBB COMPANY 373 14.1.16.1 Business overview 373 14.1.16.2 Products offered 374 14.1.16.3 Recent developments 376 14.1.16.3.1 Product launches and approvals 376 14.1.16.3.2 Deals 378 14.1.17 NOVARTIS AG 379 14.1.17.1 Business overview 379 14.1.17.2 Products offered 380 14.1.17.3 Recent developments 383 14.1.17.3.1 Product launches and approvals 383 14.1.17.3.2 Deals 384 14.1.18 ASTRAZENECA 386 14.1.18.1 Business overview 386 14.1.18.2 Products offered 387 14.1.18.3 Recent developments 389 14.1.18.3.1 Product launches and approvals 389 14.1.18.3.2 Deals 390 14.1.19 ABBVIE INC. 391 14.1.19.1 Business overview 391 14.1.19.2 Products offered 392 14.1.19.3 Recent developments 393 14.1.19.3.1 Product launches and approvals 393 14.1.19.3.2 Deals 393 14.1.19.3.3 Expansions 394 14.1.20 LILLY 395 14.1.20.1 Business overview 395 14.1.20.2 Products offered 396 14.1.20.3 Recent developments 397 14.1.20.3.1 Product launches and approvals 397 14.1.20.3.2 Deals 398 14.1.21 PFIZER INC. 399 14.1.21.1 Business overview 399 14.1.21.2 Products offered 400 14.1.21.3 Recent developments 402 14.1.21.3.1 Product launches and approvals 402 14.1.21.3.2 Deals 402 14.1.22 SAREPTA THERAPEUTICS, INC. 403 14.1.22.1 Business overview 403 14.1.22.2 Products offered 404 14.1.22.3 Recent developments 405 14.1.22.3.1 Product launches and approvals 405 14.1.22.3.2 Deals 406 14.1.23 VERTEX PHARMACEUTICALS INCORPORATED 407 14.1.23.1 Business overview 407 14.1.23.2 Products offered 408 14.1.23.3 Recent developments 409 14.1.23.3.1 Product launches and approvals 409 14.1.23.3.2 Deals 410 14.1.24 GSK PLC. 411 14.1.24.1 Business overview 411 14.1.24.2 Products offered 412 14.1.24.3 Recent developments 413 14.1.24.3.1 Product launches and approvals 413 14.1.24.3.2 Deals 414 14.2 OTHER PLAYERS 416 14.2.1 SANOFI 416 14.2.2 JOHNSON & JOHNSON SERVICES, INC. 417 14.2.3 AMGEN INC. 418 14.2.4 MERCK KGAA 419 14.2.5 ALNYLAM PHARMACEUTICALS, INC. 420 14.2.6 INCYTE 421 14.2.7 ARUP LABORATORIES 422 14.2.8 DEVYSER 423 14.2.9 DIASORIN S.P.A. 424 14.2.10 TEMPUS 426 14.2.11 PILLAR BIOSCIENCES INC. 427 14.2.12 INVIVOSCRIBE, INC. 428 14.2.13 NEUROCODE 429 14.2.14 C₂N DIAGNOSTICS 430 14.2.15 TRINITY BIOTECH 431 14.2.16 AMOY DIAGNOSTICS CO., LTD. 432 15 APPENDIX 434 15.1 DISCUSSION GUIDE 434 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 441 15.3 CUSTOMIZATION OPTIONS 443 15.4 RELATED REPORTS 444 15.5 AUTHOR DETAILS 445

TABLE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INCLUSIONS AND EXCLUSIONS 36 TABLE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RISK ASSESSMENT 52 TABLE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 65 TABLE 4 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021–2023 (USD) 71 TABLE 5 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021–2023 (USD) 72 TABLE 6 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021–2023 (USD) 73 TABLE 7 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ROLE OF COMPANIES IN ECOSYSTEM 80 TABLE 8 PRECISION MEDICINE PRODUCTS IN CLINICAL PIPELINE, 2025–2029 81 TABLE 9 PRECISION DIAGNOSTIC TESTS APPROVED BY FDA 83 TABLE 10 PRECISION DIAGNOSTIC PRODUCTS ANALYSIS 95 TABLE 11 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 99 TABLE 12 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2019–2024 101 TABLE 13 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (USD THOUSAND) 102 TABLE 14 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (TONS) 103 TABLE 15 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (USD THOUSAND) 104 TABLE 16 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (TONS) 105 TABLE 17 PRECISION DIAGNOSTICS AND MEDICINE MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 106 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111 TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111 TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 112 TABLE 23 PRECISION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 112 TABLE 24 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 114 TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE 116 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT 118 TABLE 27 BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER 119 TABLE 28 BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER 120 TABLE 29 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 125 TABLE 30 PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022–2029 (USD BILLION) 126 TABLE 31 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 126 TABLE 32 EUROPE: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 126 TABLE 33 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 127 TABLE 34 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 127 TABLE 35 PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY REGION, 2022–2029 (USD BILLION) 128 TABLE 36 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 128 TABLE 37 EUROPE: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 129 TABLE 38 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 129 TABLE 39 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 129 TABLE 40 PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY REGION, 2022–2029 (USD BILLION) 130 TABLE 41 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 130 TABLE 42 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 131 TABLE 43 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 131 TABLE 44 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 131 TABLE 45 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 133 TABLE 46 PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD BILLION) 134 TABLE 47 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 134 TABLE 48 EUROPE: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 135 TABLE 49 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 135 TABLE 50 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 135 TABLE 51 PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION) 136 TABLE 52 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 137 TABLE 53 EUROPE: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 137 TABLE 54 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 137 TABLE 55 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 138 TABLE 56 PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY REGION, 2022–2029 (USD BILLION) 139 TABLE 57 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 139 TABLE 58 EUROPE: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 139 TABLE 59 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 140 TABLE 60 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 140 TABLE 61 PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY REGION, 2022–2029 (USD BILLION) 141 TABLE 62 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 141 TABLE 63 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 141 TABLE 64 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 142 TABLE 65 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 142 TABLE 66 PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 144 TABLE 67 PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD BILLION) 145 TABLE 68 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 145 TABLE 69 EUROPE: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 145 TABLE 70 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 146 TABLE 71 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 146 TABLE 72 PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION) 147 TABLE 73 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 147 TABLE 74 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 147 TABLE 75 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 148 TABLE 76 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 148 TABLE 77 PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD BILLION) 149 TABLE 78 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 149 TABLE 79 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 149 TABLE 80 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 150 TABLE 81 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 150 TABLE 82 PRECISION MEDICINE MARKET, BY TYPE, 2022–2029 (USD BILLION) 152 TABLE 83 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2029 (USD BILLION) 153 TABLE 84 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 153 TABLE 85 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 153 TABLE 86 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 154 TABLE 87 LATIN AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 154 TABLE 88 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2022–2029 (USD BILLION) 155 TABLE 89 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 155 TABLE 90 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 156 TABLE 91 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 156 TABLE 92 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 156 TABLE 93 PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY REGION, 2022–2029 (USD BILLION) 158 TABLE 94 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD BILLION) 158 TABLE 95 EUROPE: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD BILLION) 158 TABLE 96 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD BILLION) 159 TABLE 97 LATIN AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD BILLION) 159 TABLE 98 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY REGION, 2022–2029 (USD BILLION) 160 TABLE 99 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 160 TABLE 100 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 160 TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 161 TABLE 102 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 161 TABLE 103 PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD BILLION) 162 TABLE 104 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD BILLION) 162 TABLE 105 EUROPE: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD BILLION) 162 TABLE 106 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD BILLION) 163 TABLE 107 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD BILLION) 163 TABLE 108 PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 165 TABLE 109 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD BILLION) 166 TABLE 110 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 166 TABLE 111 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 166 TABLE 112 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 167 TABLE 113 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 167 TABLE 114 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD BILLION) 168 TABLE 115 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 168 TABLE 116 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 169 TABLE 117 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 169 TABLE 118 LATIN AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 169 TABLE 119 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD BILLION) 170 TABLE 120 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 170 TABLE 121 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 171 TABLE 122 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 171 TABLE 123 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 171 TABLE 124 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD BILLION) 172 TABLE 125 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 173 TABLE 126 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 173 TABLE 127 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 173 TABLE 128 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 174 TABLE 129 PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY REGION, 2022–2029 (USD BILLION) 175 TABLE 130 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 175 TABLE 131 EUROPE: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 175 TABLE 132 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 176 TABLE 133 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 176 TABLE 134 PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD MILLION) 178 TABLE 135 PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION) 179 TABLE 136 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 179 TABLE 137 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 179 TABLE 138 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 180 TABLE 139 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 180 TABLE 140 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD MILLION) 181 TABLE 141 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 181 TABLE 142 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 182 TABLE 143 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 182 TABLE 144 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 182 TABLE 145 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION, 2022–2029 (USD BILLION) 184 TABLE 146 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 185 TABLE 147 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 186 TABLE 148 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 186 TABLE 149 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 186 TABLE 150 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 187 TABLE 151 NORTH AMERICA: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 187 TABLE 152 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 187 TABLE 153 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 188 TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 188 TABLE 155 US: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 189 TABLE 156 US: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 190 TABLE 157 US: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 190 TABLE 158 US: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 190 TABLE 159 US: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 191 TABLE 160 US: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 191 TABLE 161 CANADA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 192 TABLE 162 CANADA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 192 TABLE 163 CANADA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 192 TABLE 164 CANADA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 193 TABLE 165 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 193 TABLE 166 CANADA: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 193 TABLE 167 EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 194 TABLE 168 EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 194 TABLE 169 EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 195 TABLE 170 EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 195 TABLE 171 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 195 TABLE 172 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 196 TABLE 173 EUROPE: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 196 TABLE 174 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 196 TABLE 175 EUROPE: KEY MACROECONOMIC INDICATORS 198 TABLE 176 GERMANY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 199 TABLE 177 GERMANY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 199 TABLE 178 GERMANY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 200 TABLE 179 GERMANY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 200 TABLE 180 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 200 TABLE 181 GERMANY: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 201 TABLE 182 UK: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 202 TABLE 183 UK: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 202 TABLE 184 UK: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 202 TABLE 185 UK: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 203 TABLE 186 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 203 TABLE 187 UK: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 203 TABLE 188 FRANCE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 204 TABLE 189 FRANCE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 204 TABLE 190 FRANCE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 205 TABLE 191 FRANCE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 205 TABLE 192 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 205 TABLE 193 FRANCE: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 206 TABLE 194 ITALY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 206 TABLE 195 ITALY: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 207 TABLE 196 ITALY: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 207 TABLE 197 ITALY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 207 TABLE 198 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 208 TABLE 199 ITALY: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 208 TABLE 200 SPAIN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 209 TABLE 201 SPAIN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 209 TABLE 202 SPAIN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 209 TABLE 203 SPAIN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 210 TABLE 204 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 210 TABLE 205 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 210 TABLE 206 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 211 TABLE 207 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 211 TABLE 208 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 212 TABLE 209 REST OF EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 212 TABLE 210 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 212 TABLE 211 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 213 TABLE 212 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 213 TABLE 213 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 214 TABLE 214 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 214 TABLE 215 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 214 TABLE 216 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 215 TABLE 217 ASIA PACIFIC: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 215 TABLE 218 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 215 TABLE 219 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 216 TABLE 220 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 216 TABLE 221 CHINA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 217 TABLE 222 CHINA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 217 TABLE 223 CHINA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 218 TABLE 224 CHINA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 218 TABLE 225 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 218 TABLE 226 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 219 TABLE 227 JAPAN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 220 TABLE 228 JAPAN: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 220 TABLE 229 JAPAN: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 220 TABLE 230 JAPAN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 221 TABLE 231 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 221 TABLE 232 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 221 TABLE 233 INDIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 222 TABLE 234 INDIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 222 TABLE 235 INDIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 223 TABLE 236 INDIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 223 TABLE 237 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 223 TABLE 238 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 224 TABLE 239 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 224 TABLE 240 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 225 TABLE 241 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 225 TABLE 242 AUSTRALIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 225 TABLE 243 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 226 TABLE 244 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 226 TABLE 245 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 226 TABLE 246 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 227 TABLE 247 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 227 TABLE 248 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 227 TABLE 249 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 228 TABLE 250 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 228 TABLE 251 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 229 TABLE 252 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 229 TABLE 253 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 229 TABLE 254 LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 230 TABLE 255 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 230 TABLE 256 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 230 TABLE 257 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 231 TABLE 258 LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 231 TABLE 259 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 232 TABLE 260 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 233 TABLE 261 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 233 TABLE 262 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 233 TABLE 263 BRAZIL: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 234 TABLE 264 BRAZIL: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 234 TABLE 265 BRAZIL: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 234 TABLE 266 MEXICO: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 235 TABLE 267 MEXICO: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 235 TABLE 268 MEXICO: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 236 TABLE 269 MEXICO: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 236 TABLE 270 MEXICO: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 236 TABLE 271 MEXICO: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 237 TABLE 272 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 237 TABLE 273 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 238 TABLE 274 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 238 TABLE 275 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 238 TABLE 276 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 239 TABLE 277 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 239 TABLE 278 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 240 TABLE 279 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 240 TABLE 280 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 241 TABLE 281 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 241 TABLE 282 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 241 TABLE 283 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 242 TABLE 284 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 243 TABLE 285 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION DIAGNOSTICS MARKET, JANUARY 2021–NOVEMBER 2024 245 TABLE 286 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION MEDICINE MARKET, JANUARY 2021–NOVEMBER 2024 248 TABLE 287 PRECISION DIAGNOSTICS MARKET: DEGREE OF COMPETITION 255 TABLE 288 PRECISION MEDICINE MARKET: DEGREE OF COMPETITION 258 TABLE 289 PRECISION DIAGNOSTICS MARKET: REGION FOOTPRINT 263 TABLE 290 PRECISION DIAGNOSTICS MARKET: TYPE FOOTPRINT 264 TABLE 291 PRECISION DIAGNOSTICS MARKET: INDICATION FOOTPRINT 265 TABLE 292 PRECISION MEDICINE MARKET: REGION FOOTPRINT 270 TABLE 293 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT 271 TABLE 294 PRECISION MEDICINE MARKET: INDICATION FOOTPRINT 272 TABLE 295 PRECISION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 276 TABLE 296 PRECISION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 277 TABLE 297 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES 280 TABLE 298 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 281 TABLE 299 PRECISION DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 286 TABLE 300 PRECISION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 287 TABLE 301 PRECISION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 288 TABLE 302 PRECISION MEDICINE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 289 TABLE 303 PRECISION MEDICINE MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 290 TABLE 304 PRECISION MEDICINE: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 291 TABLE 305 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY OVERVIEW 292 TABLE 306 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCTS OFFERED 293 TABLE 307 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 297 TABLE 308 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): DEALS, JANUARY 2021–NOVEMBER 2024 298 TABLE 309 ABBOTT: COMPANY OVERVIEW 300 TABLE 310 ABBOTT: PRODUCTS OFFERED 301 TABLE 311 ABBOTT: DEALS, JANUARY 2021–NOVEMBER 2024 302 TABLE 312 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 304 TABLE 313 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 305 TABLE 314 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 307 TABLE 315 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 308 TABLE 316 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 308 TABLE 317 GUARDANT HEALTH: COMPANY OVERVIEW 310 TABLE 318 GUARDANT HEALTH: PRODUCTS OFFERED 311 TABLE 319 GUARDANT HEALTH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 312 TABLE 320 GUARDANT HEALTH: DEALS, JANUARY 2021–NOVEMBER 2024 314 TABLE 321 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 316 TABLE 322 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED 317 TABLE 323 EXACT SCIENCES CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 318 TABLE 324 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 319 TABLE 325 QIAGEN: COMPANY OVERVIEW 320 TABLE 326 QIAGEN: PRODUCTS OFFERED 321 TABLE 327 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 324 TABLE 328 QIAGEN: DEALS, JANUARY 2021–NOVEMBER 2024 325 TABLE 329 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 326 TABLE 330 MYRIAD GENETICS, INC.: PRODUCTS OFFERED 327 TABLE 331 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 329 TABLE 332 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 329 TABLE 333 MYRIAD GENETICS, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 330 TABLE 334 NATERA, INC.: COMPANY OVERVIEW 331 TABLE 335 NATERA, INC.: PRODUCTS OFFERED 332 TABLE 336 NATERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 334 TABLE 337 NATERA, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 334 TABLE 338 ILLUMINA, INC.: COMPANY OVERVIEW 335 TABLE 339 ILLUMINA, INC.: PRODUCTS OFFERED 336 TABLE 340 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 337 TABLE 341 ILLUMINA, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 337 TABLE 342 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 339 TABLE 343 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 340 TABLE 344 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 341 TABLE 345 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–NOVEMBER 2024 342 TABLE 346 DANAHER: COMPANY OVERVIEW 344 TABLE 347 DANAHER: PRODUCTS OFFERED 345 TABLE 348 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 348 TABLE 349 DANAHER: DEALS, JANUARY 2021–NOVEMBER 2024 349 TABLE 350 23ANDME, INC.: COMPANY OVERVIEW 350 TABLE 351 23ANDME, INC.: PRODUCTS OFFERED 351 TABLE 352 23ANDME, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 353 TABLE 353 MERCK & CO., INC.: COMPANY OVERVIEW 354 TABLE 354 MERCK & CO., INC.: PRODUCTS OFFERED 355 TABLE 355 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 356 TABLE 356 MERCK & CO., INC.: DEALS, JANUARY 2021–NOVEMBER 2024 360 TABLE 357 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 361 TABLE 358 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 362 TABLE 359 GILEAD SCIENCES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 364 TABLE 360 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 365 TABLE 361 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY OVERVIEW 367 TABLE 362 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCTS OFFERED 368 TABLE 363 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 371 TABLE 364 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 373 TABLE 365 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 374 TABLE 366 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 376 TABLE 367 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–NOVEMBER 2024 378 TABLE 368 NOVARTIS AG: COMPANY OVERVIEW 379 TABLE 369 NOVARTIS AG: PRODUCTS OFFERED 380 TABLE 370 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 383 TABLE 371 NOVARTIS AG: DEALS, JANUARY 2021–NOVEMBER 2024 384 TABLE 372 ASTRAZENECA: COMPANY OVERVIEW 386 TABLE 373 ASTRAZENECA: PRODUCTS OFFERED 387 TABLE 374 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 389 TABLE 375 ASTRAZENECA: DEALS, JANUARY 2021–NOVEMBER 2024 390 TABLE 376 ABBVIE INC.: COMPANY OVERVIEW 391 TABLE 377 ABBVIE INC.: PRODUCTS OFFERED 392 TABLE 378 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 393 TABLE 379 ABBVIE INC.: DEALS, JANUARY 2021–NOVEMBER 2024 393 TABLE 380 ABBVIE INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 394 TABLE 381 LILLY: COMPANY OVERVIEW 395 TABLE 382 LILLY: PRODUCTS OFFERED 396 TABLE 383 LILLY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 397 TABLE 384 LILLY: DEALS, JANUARY 2021–NOVEMBER 2024 398 TABLE 385 PFIZER INC.: COMPANY OVERVIEW 399 TABLE 386 PFIZER INC.: PRODUCTS OFFERED 400 TABLE 387 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 402 TABLE 388 PFIZER INC.: DEALS, JANUARY 2021–NOVEMBER 2024 402 TABLE 389 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 403 TABLE 390 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 404 TABLE 391 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 405 TABLE 392 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 406 TABLE 393 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW 407 TABLE 394 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS OFFERED 408 TABLE 395 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 409 TABLE 396 VERTEX PHARMACEUTICALS INCORPORATED: DEALS, JANUARY 2021–NOVEMBER 2024 410 TABLE 397 GSK PLC.: COMPANY OVERVIEW 411 TABLE 398 GSK PLC.: PRODUCTS OFFERED 412 TABLE 399 GSK PLC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 413 TABLE 400 GSK PLC.: DEALS, JANUARY 2021–NOVEMBER 2024 414 TABLE 401 SANOFI: COMPANY OVERVIEW 416 TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 417 TABLE 403 AMGEN INC.: COMPANY OVERVIEW 418 TABLE 404 MERCK KGAA: COMPANY OVERVIEW 419 TABLE 405 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 420 TABLE 406 INCYTE: COMPANY OVERVIEW 421 TABLE 407 ARUP LABORATORIES: COMPANY OVERVIEW 422 TABLE 408 DEVYSER: COMPANY OVERVIEW 423 TABLE 409 DIASORIN S.P.A.: COMPANY OVERVIEW 424 TABLE 410 TEMPUS: COMPANY OVERVIEW 426 TABLE 411 PILLAR BIOSCIENCES INC.: COMPANY OVERVIEW 427 TABLE 412 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 428 TABLE 413 NEUROCODE: COMPANY OVERVIEW 429 TABLE 414 C₂N DIAGNOSTICS: COMPANY OVERVIEW 430 TABLE 415 TRINITY BIOTECH: COMPANY OVERVIEW 431 TABLE 416 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 432 FIGURE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET SEGMENTATION 35 FIGURE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RESEARCH DESIGN 39 FIGURE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 41 FIGURE 4 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 42 FIGURE 5 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42 FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE ANALYSIS, 2023 43 FIGURE 7 PRECISION MEDICINE MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 44 FIGURE 8 PRECISION MEDICINE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 45 FIGURE 9 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS, 2023 45 FIGURE 10 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 46 FIGURE 11 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 47 FIGURE 12 PRECISION MEDICINE MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 48 FIGURE 13 PRECISION DIAGNOSTICS MARKET: CAGR PROJECTIONS, 2024–2029 49 FIGURE 14 PRECISION MEDICINE MARKET: CAGR PROJECTIONS, 2024–2029 50 FIGURE 15 PRECISION DIAGNOSTICS AND MEDICINE MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 50 FIGURE 16 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DATA TRIANGULATION 51 FIGURE 17 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 53 FIGURE 18 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION) 54 FIGURE 19 PRECISION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 54 FIGURE 20 PRECISION MEDICINE MARKET, BY PRODUCT, 2024 VS. 2029 (USD BILLION) 55 FIGURE 21 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION) 55 FIGURE 22 PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 56 FIGURE 23 GEOGRAPHICAL SNAPSHOT OF PRECISION DIAGNOSTICS MARKET, 2024–2029 56 FIGURE 24 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET, 2024–2029 57 FIGURE 25 INCREASING DEMAND FOR QUICK AND ACCURATE DIAGNOSTIC TESTS TO DRIVE PRECISION DIAGNOSTICS MARKET 58 FIGURE 26 INCREASING NUMBER OF REGULATORY APPROVALS FOR PERSONALIZED MEDICINES TO DRIVE PRECISION MEDICINE MARKET 59 FIGURE 27 GENETIC TESTING SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF PRECISION DIAGNOSTICS MARKET IN 2023 60 FIGURE 28 ONCOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD 60 FIGURE 29 HOME CARE SETTINGS MARKET COMMANDED HIGHEST SHARE IN 2023 61 FIGURE 30 MONOCLONAL ANTIBODIES AND US LED NORTH AMERICAN PRECISION MEDICINE MARKET IN 2023 61 FIGURE 31 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 32 JAPAN TO REGISTER HIGHEST GROWTH IN PRECISION DIAGNOSTICS MARKET DURING FORECAST PERIOD 62 FIGURE 33 GERMANY TO REGISTER HIGHEST GROWTH IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD 63 FIGURE 34 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 35 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PRECISION DIAGNOSTICS AND MEDICINE MARKET 70 FIGURE 36 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021–2023 (USD) 71 FIGURE 37 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER, 2021–2023 (USD) 73 FIGURE 38 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY REGION, 2021–2023 (USD) 74 FIGURE 39 PRECISION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 75 FIGURE 40 PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS 76 FIGURE 41 PRECISION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 78 FIGURE 42 PRECISION MEDICINE MARKET: SUPPLY CHAIN ANALYSIS 79 FIGURE 43 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ECOSYSTEM ANALYSIS 80 FIGURE 44 PRECISION DIAGNOSTICS AND MEDICINE MARKET: PATENT ANALYSIS, JANUARY 2014–NOVEMBER 2024 100 FIGURE 45 PRECISION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 113 FIGURE 46 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 115 FIGURE 47 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE 117 FIGURE 48 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT 118 FIGURE 49 KEY BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER 119 FIGURE 50 KEY BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER 120 FIGURE 51 NORTH AMERICA: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT 185 FIGURE 52 EUROPE: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT 197 FIGURE 53 PRECISION DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 252 FIGURE 54 PRECISION MEDICINE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 253 FIGURE 55 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 254 FIGURE 56 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 257 FIGURE 57 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 261 FIGURE 58 PRECISION DIAGNOSTICS MARKET: COMPANY FOOTPRINT 262 FIGURE 59 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 268 FIGURE 60 PRECISION MEDICINE MARKET: COMPANY FOOTPRINT 269 FIGURE 61 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 275 FIGURE 62 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 279 FIGURE 63 PRECISION DIAGNOSTICS MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 282 FIGURE 64 PRECISION DIAGNOSTICS MARKET: EV/EBITDA OF KEY VENDORS, 2024 282 FIGURE 65 PRECISION MEDICINE MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 283 FIGURE 66 PRECISION MEDICINE MARKET: EV/EBITDA OF KEY VENDORS, 2024 283 FIGURE 67 PRECISION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON 284 FIGURE 68 PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARISON 285 FIGURE 69 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY SNAPSHOT (2023) 293 FIGURE 70 ABBOTT: COMPANY SNAPSHOT (2023) 301 FIGURE 71 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 305 FIGURE 72 GUARDANT HEALTH: COMPANY SNAPSHOT (2023) 311 FIGURE 73 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 317 FIGURE 74 QIAGEN: COMPANY SNAPSHOT (2023) 321 FIGURE 75 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) 327 FIGURE 76 NATERA, INC.: COMPANY SNAPSHOT (2023) 332 FIGURE 77 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 336 FIGURE 78 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 340 FIGURE 79 DANAHER: COMPANY SNAPSHOT (2023) 345 FIGURE 80 23ANDME, INC.: COMPANY SNAPSHOT (2023) 351 FIGURE 81 MERCK & CO., INC.: COMPANY SNAPSHOT (2023) 355 FIGURE 82 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023) 362 FIGURE 83 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY SNAPSHOT (2023) 368 FIGURE 84 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023) 374 FIGURE 85 NOVARTIS AG: COMPANY SNAPSHOT (2023) 380 FIGURE 86 ASTRAZENECA: COMPANY SNAPSHOT (2023) 387 FIGURE 87 ABBVIE INC.: COMPANY SNAPSHOT (2023) 392 FIGURE 88 LILLY: COMPANY SNAPSHOT (2023) 396 FIGURE 89 PFIZER INC.: COMPANY SNAPSHOT (2023) 400 FIGURE 90 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2023) 404 FIGURE 91 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2023) 408 FIGURE 92 GSK PLC.: COMPANY SNAPSHOT (2023) 412